These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27333728)

  • 21. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Lahoz R; Reynolds T; Korn JR
    Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
    J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
    BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic interference with leukocyte recirculation in multiple sclerosis.
    Sellebjerg F; Sørensen PS
    Eur J Neurol; 2015 Mar; 22(3):434-42. PubMed ID: 25582213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple sclerosis, a treatable disease .
    Doshi A; Chataway J
    Clin Med (Lond); 2017 Dec; 17(6):530-536. PubMed ID: 29196354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies.
    Berger JR
    Am J Manag Care; 2011 May; 17 Suppl 5 Improving():S146-53. PubMed ID: 21761953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.
    Noon KM; Montgomery SM; Adlard NE; Kroes MA
    J Med Econ; 2018 Oct; 21(10):983-992. PubMed ID: 29923439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.
    Bianco A; Patanella AK; Nociti V; Marti A; Frisullo G; Plantone D; De Fino C; Fetta A; Batocchi AP; Rossini PM; Mirabella M
    Eur Neurol; 2015; 73(1-2):57-65. PubMed ID: 25402749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease-modifying therapies and infectious risks in multiple sclerosis.
    Winkelmann A; Loebermann M; Reisinger EC; Hartung HP; Zettl UK
    Nat Rev Neurol; 2016 Apr; 12(4):217-33. PubMed ID: 26943779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
    O'Day K; Meyer K; Miller RM; Agarwal S; Franklin M
    J Med Econ; 2011; 14(5):617-27. PubMed ID: 21777161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis.
    Dubey D; Cano CA; Stüve O
    Curr Opin Neurol; 2016 Jun; 29(3):278-85. PubMed ID: 27027553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [[Natalizumab therapy, 2013].
    Karácsony M; Bencsik K; Vécsei L
    Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm.
    Cree BAC; Mares J; Hartung HP
    Curr Opin Neurol; 2019 Jun; 32(3):365-377. PubMed ID: 30985372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.
    Puz P; Lasek-Bal A
    Med Sci Monit; 2016 Nov; 22():4277-4282. PubMed ID: 27829656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.
    Montgomery SM; Kusel J; Nicholas R; Adlard N
    J Med Econ; 2017 Sep; 20(9):962-973. PubMed ID: 28635362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.
    Zivadinov R; Medin J; Khan N; Korn JR; Chitnis T; Naismith RT; Alvarez E; Dwyer MG; Bergsland N; Carl E; Silva D; Weinstock-Guttman B;
    Mult Scler Relat Disord; 2019 Jan; 27():65-73. PubMed ID: 30342416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.
    Zivadinov R; Medin J; Khan N; Korn JR; Bergsland N; Dwyer MG; Chitnis T; Naismith RT; Alvarez E; Kinkel P; Cohan S; Hunter SF; Silva D; Weinstock-Guttman B;
    J Neuroimaging; 2018 Jul; 28(4):399-405. PubMed ID: 29749661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.
    Rommer PS; Zettl UK
    Expert Opin Pharmacother; 2018 Apr; 19(5):483-498. PubMed ID: 29528247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.